Non-Small Cell Lung Cancer - Pipeline Review, H1 2017

Published: Jun, 2017 | Pages: 2437 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2017, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 49, 192, 176, 1, 11, 173, 20 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 13, 11, 1, 40 and 4 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 13
Non-Small Cell Lung Cancer - Overview 14
Non-Small Cell Lung Cancer - Therapeutics Development 15
Non-Small Cell Lung Cancer - Therapeutics Assessment 84
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 118
Non-Small Cell Lung Cancer - Drug Profiles 278
Non-Small Cell Lung Cancer - Dormant Projects 2323
Non-Small Cell Lung Cancer - Discontinued Products 2343
Non-Small Cell Lung Cancer - Product Development Milestones 2351
Appendix 2369

List of Tables

Number of Products under Development for Non-Small Cell Lung Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..19), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Products under Development by Companies, H1 2017 (Contd..19), H1 2017
Products under Development by Companies, H1 2017 (Contd..20), H1 2017
Products under Development by Companies, H1 2017 (Contd..21), H1 2017
Products under Development by Companies, H1 2017 (Contd..22), H1 2017
Products under Development by Companies, H1 2017 (Contd..23), H1 2017
Products under Development by Companies, H1 2017 (Contd..24), H1 2017
Products under Development by Companies, H1 2017 (Contd..25), H1 2017
Products under Development by Companies, H1 2017 (Contd..26), H1 2017
Products under Development by Companies, H1 2017 (Contd..27), H1 2017
Products under Development by Companies, H1 2017 (Contd..28), H1 2017
Products under Development by Companies, H1 2017 (Contd..29), H1 2017
Products under Development by Companies, H1 2017 (Contd..30), H1 2017
Products under Development by Companies, H1 2017 (Contd..31), H1 2017
Products under Development by Companies, H1 2017 (Contd..32), H1 2017
Products under Development by Companies, H1 2017 (Contd..33), H1 2017
Products under Development by Companies, H1 2017 (Contd..34), H1 2017
Products under Development by Companies, H1 2017 (Contd..35), H1 2017
Products under Development by Companies, H1 2017 (Contd..36), H1 2017
Products under Development by Companies, H1 2017 (Contd..37), H1 2017
Products under Development by Companies, H1 2017 (Contd..38), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..13), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..13), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2017
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2017
Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Apexigen Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Arog Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Aurobindo Pharma Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Axelar AB, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2017
Non-Small Cell Lung Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by BerGenBio ASA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Bicycle Therapeutics Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Bio-Path Holdings Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Biocad, H1 2017
Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by CanBas Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Cascadian Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by CBT Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Celgene Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Cellectar Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Cellmid Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Cielo Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Cipla Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Cleave Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Cortice Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H1 2017
Non-Small Cell Lung Cancer - Pipeline by CytImmune Sciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by CytRx Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by DAE HWA Pharmaceutical Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Debiopharm International SA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma LLC, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Domainex Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Dynavax Technologies Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Eisai Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Endocyte Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by EntreChem SL, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Enumeral Biomedical Holdings Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by EpiThany Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Etubics Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Eudendron Srl, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Evotec AG, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Exelixis Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by FibroStatin SL, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Formosa Laboratories Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Fujifilm Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Galectin Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Gene Techno Science Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Genelux Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Genentech Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Genmab A/S, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Genocea Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Genor BioPharma Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Genosco Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Genzyme Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Globeimmune Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Glycotope GmbH, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Gradalis Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by GreenPeptide Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Griffith University, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Grunenthal GmbH, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Halozyme Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Heat Biologics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Hemispherx Biopharma Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Heptares Therapeutics Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by HitGen LTD, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Humorigin Biotechnology Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Hutchison China MediTech Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by iCeutica Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Ideaya Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Ignyta Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by ImmunGene Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Immunocore Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by ImmunoGen Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Immunomedics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Incyte Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Infinity Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Inflection Biosciences Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Innovent Biologics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Intas Pharmaceuticals Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Invectys SA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Inventiva, H1 2017
Non-Small Cell Lung Cancer - Pipeline by IO Biotech ApS, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Io Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by JHL Biotech Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Jounce Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Juno Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Kadmon Corp LLC, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Kite Pharma Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Komipharm International Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Kura Oncology Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Leap Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Lion Biotechnologies Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Lipopharma Therapeutics SL, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Loxo Oncology Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Mabion SA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by MacroGenics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Mallinckrodt Plc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Mebiopharm Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by MedImmune LLC, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Merck & Co Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Merck KGaA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Mersana Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Merus NV, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Microlin Bio Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Molecular Partners AG, H1 2017
Non-Small Cell Lung Cancer - Pipeline by MolMed SpA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Morphotek Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Multimmune GmbH, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Mycenax Biotech Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by NanoCarrier Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by NantKwest Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Natco Pharma Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Neumedicines Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by NewLink Genetics Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Northwest Biotherapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Oncobiologics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Oncogenex Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Oncolys BioPharma Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Oncolytics Biotech Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Onxeo SA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Optimum Therapeutics LLC, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Oribase Pharma, H1 2017
Non-Small Cell Lung Cancer - Pipeline by OSE Immunotherapeutics, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Pfizer Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Pharma Mar SA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Philogen SpA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Phosplatin Therapeutics LLC, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Plexxikon Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by PsiOxus Therapeutics Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Puma Biotechnology Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Purdue Pharma LP, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Qilu Pharmaceutical Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Qu Biologics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Quintessence Biosciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Qurient Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Rafael Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Reata Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Recombio SL, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Rgenix Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Richter Gedeon Nyrt, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Samyang Holdings Corp, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Sanofi, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Scancell Holdings Plc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by SciClone Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by ScinoPharm Taiwan Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Seattle Genetics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Selvita SA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Shionogi & Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Sierra Oncology Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Sigma-Tau SpA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by SignPath Pharma Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Sotio AS, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Spotlight Innovation Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Starpharma Holdings Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by SuviCa Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Symic Biomedical Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Symphogen A/S, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Synactix Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Synermore Biologics Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Systimmune Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Takara Bio Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by TC BioPharm Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Tocagen Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Transgene SA, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Trovagene Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Tyme Technologies Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by UbiVac LLC, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Ultimovacs AS, H1 2017
Non-Small Cell Lung Cancer - Pipeline by United BioPharma Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Vaccinex Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by VasGene Therapeutics Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Vault Pharma Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Vaxon Biotech, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Verastem Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by VG Life Sciences Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by ViiV Healthcare Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Viralytics Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by XBiotech Inc, H1 2017
Non-Small Cell Lung Cancer - Pipeline by XuanZhu Pharma Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Yooyoung Pharm Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Non-Small Cell Lung Cancer - Pipeline by Zymeworks Inc, H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..6), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..7), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..8), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..9), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..10), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..11), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..12), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..13), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..14), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..15), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..16), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..17), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..18), H1 2017
Non-Small Cell Lung Cancer - Dormant Projects, H1 2017 (Contd..19), H1 2017
Non-Small Cell Lung Cancer - Discontinued Products, H1 2017
Non-Small Cell Lung Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017
Non-Small Cell Lung Cancer - Discontinued Products, H1 2017 (Contd..2), H1 2017
Non-Small Cell Lung Cancer - Discontinued Products, H1 2017 (Contd..3), H1 2017
Non-Small Cell Lung Cancer - Discontinued Products, H1 2017 (Contd..4), H1 2017
Non-Small Cell Lung Cancer - Discontinued Products, H1 2017 (Contd..5), H1 2017
Non-Small Cell Lung Cancer - Discontinued Products, H1 2017 (Contd..6), H1 2017
Non-Small Cell Lung Cancer - Discontinued Products, H1 2017 (Contd..7), H1 2017